Background: Psoriasis is a chronic disease that may require long-term treatment. Ixekizumab (IXE), which is a high-affinity monoclonal antibody that selectively targets interleukin 17A, is an approved therapy for patients with moderate-to-severe plaque psoriasis.
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Ixekizumab (IXE), a highaffinity monoclonal antibody that selectively targets interleukin 17A, 1 has been approved for the treatment of patients with moderateto-severe plaque psoriasis. Long-term efficacy and safety treatment outcomes remain essential given the chronicity of plaque psoriasis. Previously, the efficacy and safety of IXE had been reported up to 1 year 2,3 and 2 years. 2 Within this article, we have presented the outcomes of IXE treatment from the UNCOVER-3 study through 3 years (156 weeks).
METHODS

Study design and participants
UNCOVER-3 (NCT01646177) was a randomized, double-blind, multicenter, phase 3 study in patients with moderate-to-severe plaque psoriasis. Details of the study design and patient population have been reported previously. 3, 4 In this study, patients were randomized to receive either placebo, 80 mg of IXE every 2 weeks, 80 mg of IXE every 4 weeks (with both groups receiving IXE as a starting dose of 160 mg), or 50 mg of etanercept twice weekly. At week 12, all patients were switched to a dose of IXE every 4 weeks for the long-term extension (LTE). After week 60 and at the investigator's discretion, patients could receive a dose adjustment to IXE every 2 weeks. This report focuses on the data from patients who received the clinically recommended dosing regimen (an initial dose of 160 mg of IXE every 2 weeks up to week 12 and IXE every 4 weeks thereafter).
The study protocol was approved by the institutional review board or ethics committee at each participating site and conducted according to the principles of the Declaration of Helsinki. All eligible patients provided written informed consent before undergoing study-related procedures.
Endpoints and outcome assessment
The efficacy endpoints were the percentage of patients who achieved at least a 75%, 90%, or 100% improvement from baseline in their Psoriasis Area and Severity Index score (PASI 75, PASI 90, and PASI 100, respectively), the percentage of patients who achieved a static Physician's Global Assessment (sPGA) score of 1 (clear or minimal) or 0 (clear), and absolute PASI score. For patients who had baseline scalp, nail, or palmoplantar involvement, efficacy was evaluated on the basis of the percentage of patients achieving complete resolution as determined by their Psoriasis Scalp Severity Index score, their Nail Psoriasis Severity Index score, or a 100% improvement from baseline in the Palmoplantar Psoriasis Area and Severity Index.
Safety was evaluated in all patients who received at least 1 dose of IXE and was reported in terms of treatment-emergent adverse events (TEAEs). Selected adverse events (AEs) of special interest included infections, malignancies, neutropenia, Crohn's disease, ulcerative colitis, and cerebrocardiovascular events. Cerebrocardiovascular events were adjudicated in a blinded manner by an independent committee of experts.
Statistical analysis
For efficacy, all randomized patients (the intent-to-treat population), regardless of treatment compliance, were analyzed. Efficacy data were included from only those visits during which patients were treated with the recommended IXE dosing regimen, whereas data collected at visits with IXE dose adjustments every 2 weeks were excluded before application of any summary or imputations. Efficacy data were summarized through 156 weeks with the use of 3 methods: as-observed, multiple
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imputation (MI), and a modified nonresponder imputation (mNRI) (consisting of combined MI and nonresponder imputation, which was previously referenced as modified MI 2 ). In the as-observed method, analyses were performed on data from patients whose observations were available and did not require any imputation for missing values. In the MI method, missing data were imputed to estimate the observations that would have been made, had the patient continued the study drug. Specifically, for the intermittent/nonmonotonic missing data, the Markov chain Monte Carlo method with the simple imputation model was used; for the monotonic missing data, a sequential regression MI with the baseline score was used. In the mNRI method, patients who discontinued the study drug because of AEs, lack of efficacy, or relapse were considered nonresponders and the data were imputed as nonresponder imputation; in all other cases of missing data, the data were imputed by using the MI method as already described.
TEAEs were summarized in terms of cumulative frequencies through the LTE period for the LTE population. Percentage of patients achieving a Psoriasis Area and Severity Index (PASI) response over time through 156 weeks with the recommended ixekizumab (IXE) dosing regimen (modified nonresponder imputation; intent-totreat population). PASI 75, rate of achievement of a 75% improvement from baseline in PASI score; PASI 90, a 90% improvement from baseline in PASI score; PASI 100, a 100% improvement from baseline in PASI score, at each postbaseline visit for the dosing regimen of IXE every 2 weeks/every 4 weeks. Error bars represent 95% confidence intervals. 2-4 Through 3 years, the retention rates were high. Reasons for discontinuation were AEs (8.2%), decision of the patient (4.5%), lack of efficacy (3.0%), loss to follow-up (2.6%), and other (4.4%).
RESULTS
Of
Efficacy
High levels of clinical response were maintained throughout the 3-year treatment period. Of the patients randomized to a dose of IXE every 2 weeks/IXE every 4 weeks (n = 385), 80.5%, 66.0%, and 45.1% achieved PASI 75, 90 and 100 at week 156 with use of the mNRI method, respectively (Fig 1) . When the as-observed and MI methods were used, PASI 75 was achieved in 97.2% and 86.2% of cases, respectively ( Supplemental Fig 1, A; available at http://www.jaad.org). Similarly, 86.7% and 69.5% of patients achieved PASI 90 ( Supplemental Fig 1, B ; available at http://www.jaad.org) and 63.9% and 46.8% achieved PASI 100 ( Supplemental Fig 1, C ; available at http://www.jaad.org) at week 156 with use of the as-observed and MI methods, respectively. Additionally, IXE treatment showed consistently high rates of sPGA scores of 0 or 1 (Fig 2, A) and sPGA scores of 0 (Fig 2, B) for 3 years (rates of an sPGA score of 0 or 1 with use of the as-observed, MI, and mNRI methods of 85.1%, 72.8%, and 67.4%, respectively, and rates of an sPGA score of 0 of 63.9%, 52.1%, and 48.5%, respectively). The percentages of patients with absolute PASI scores at week 156 according to the as-observed, MI, and mNRI methods, respectively, were 97.6%, 86.1%, and 80% for a PASI score of 5 or lower; 92%, 77.1%, and 72.6% for a PASI score of 3 or lower; 89.2%, 71.7%, and 68.1% for a PASI score of 2 or lower; and 80.7%, 62.1%, and 59.3%, for a PASI score of 1 or lower. High-efficacy responses were also observed in patients with the dosing regimen of IXE every 2 weeks/every 4 weeks (156 weeks) and data from visits during which the dose was adjusted to IXE every 2 weeks (Supplemental Table I ; available at http://www.jaad.org). Sustained complete resolution throughout the 3-year treatment period was further observed in patients with baseline nail, scalp, and palmoplantar involvement (Fig 3, A-C ) ; with use of the as-observed, MI, and mNRI methods, their respective rates of resolution were as follows: 77.2%, 65.4%, and 62.4% with a Nail Psoriasis Severity Index score of 0; 86.7%, 70.6%, and 66.2% with a Psoriasis Scalp Severity Index score of 0; and 84.7%, 63.8%, and 60.5% with a 100% improvement from baseline in the Palmoplantar Psoriasis Area and Severity Index.
Between weeks 60 and 156, 182 of 1274 patients in the LTE (14.3%) had dose adjustments to IXE every 2 weeks, including 55 of 362 (15.2%) patients in the LTE who were receiving the recommended dose (IXE every 2 weeks/IXE every 4 weeks). Of interest, at the visit during which the investigator decided to adjust the dose, 41.7% (n = 23) of patients who were ETN, Etanercept, 50 mg twice weekly; IXE, ixekizumab; LTE, long-term extension; PBO, placebo administered with 2 injections in week 0, then every 2 weeks; Q2W, ixekizumab, 80 mg every 2 weeks; Q4W, ixekizumab, 80 mg every 4 weeks. *Adverse events include events that first occurred or worsened during the LTE treatment period. Adverse events reported here are cumulative and include events from the LTE population that occurred during the treatment period before the 156-week database lock. y For patients with more than 1 occurrence of the same event, severity was categorized on the basis of the most severe event.
z Common adverse events included any adverse event occurring at a rate of more than 6% in the total LTE population.
x Cerebrocardiovascular events were included only if they were confirmed by adjudication. k Candida infections include Medical Dictionary for Regulatory Activities high-level terms and Medical Dictionary for Regulatory Activities preferred terms for events likely representing Candida infections. Specific terms include vulvovaginal candidiasis, vulvovaginal mycotic infection, oral candidiasis, oropharyngeal candidiasis, Candida infection, skin Candida, oral fungal infection, balanitis Candida, nail Candida, and genital candidiasis. { Treatment-emergent neutropenia is reported for patients who experienced a worsening from baseline neutrophil counts at any time during the LTE. Percentages are calculated on the basis of the number of patients with a baseline and at least 1 postbaseline neutrophil measurement (PBO/IXE Q4W = 183, ETN/IXE Q4W = 369, IXE Q4W/IXE Q4W = 360, IXE Q2W/Q4W = 362, and total = 1274). Neutropenia grades are defined as follows: grade 1, \2000/mm 3 and $1500/mm receiving IXE every 2 weeks/every 4 weeks had mild disease activity (sPGA score, #2); PASI 75, 90, and 100 responses were achieved by 52.7% (n = 29), 21.8% (n = 12), and 0% (n = 0) of patients, respectively. Table I presents the cumulative AE profile observed across the long-term treatment period through 156 weeks. Most TEAEs were mild or moderate in severity. Among the AEs of special interest, infections were the most frequently reported (mainly viral and upper respiratory tract infections). AEs associated with duration, such as malignancies, were rare. Nonmelanoma skin cancer was reported in 0.5% of patients (n = 7). Clinically significant (grade 3 or 4) neutropenia was also infrequent, occurring in 10 patients (0.8%).
Safety
During the LTE period, 14.8% of all patients (n = 188) reported serious AEs; 10.8% of the AEs (n = 39) were observed in patients who were receiving IXE every 2 weeks/IXE every 4 weeks. Two deaths occurred in the third year of the assessment period (1 due to an unknown cause and 1 due to synovial sarcoma that occurred about 2 years after the patient was discontinued from the study).
DISCUSSION
UNCOVER-3 is a randomized, double-blind, multicenter, phase 3 study that evaluated the long-term efficacy and safety of IXE for treating moderate-to-severe plaque psoriasis. Recently (in 2017), Blauvelt et al 2 showed that IXE was well tolerated and provided a persistent and long-term clinical response through 108 weeks of treatment in patients with moderate-to-severe plaque psoriasis. The present report extends and confirms these findings by presenting persistent high clearance rates through 3 years with no new safety signals. Over 3 years of IXE treatment, 70% of patients showed a PASI 90 response and more than 50% of patients achieved PASI 100. Similarly, high response rates were observed for hard-to-treat areas (scalp, nails, and palmoplantar psoriasis). Absolute PASI scores were also low, corresponding to the high clearance rate observed compared with baseline. These efficacy findings are from patients who received the recommended dosing regimen, which provides expectations that patients in clinical practice will have similarly high rates of efficacy maintained over long-term treatment.
Consistent findings were observed regardless of which statistical method was used for handling missing data or whether data from visits with dose titration were included. The results of MI analysis were consistent with recent recommendations, such as those provided in 2017 by Langley et al, 5 who advocated that different methods are required to provide insights into different clinical questions. As-observed analysis provides estimates for patients who continue to receive treatment and are adherent, but it may overestimate the efficacy because it does not take into account clinical outcomes that result in noncompliance. The MI method addresses the question of the likelihood of results being observed in patients when there are nonclinical reasons for noncompliance, whereas the mNRI method accounts for clinical outcomes related to negative treatment effects (intolerance and lack of efficacy). Thus, by presenting these different ways of handling missing data, clinicians can make inferences about efficacy in the context of different clinical practice scenarios.
The safety profile presented here is consistent with that reported previously during the induction period 3 and after 108 weeks of IXE treatment. 2 The majority of AEs were mild to moderate in severity, and only a low percentage of patients discontinued treatment as a result of AEs (7.2% [n = 92]) during the LTE period. These safety findings support the consistency of the IXE safety profile and suggest no new signals occurring with longer exposure.
A key strength of this study is the availability of continuous data on long-term IXE treatment in patients with psoriasis. However, the flexibility of increasing the IXE dose in the study may not be feasible in clinical practice. Nonetheless, by excluding the data from the visits with adjustments of IXE dose every 2 weeks, the study methodology provides generalizability of the results to clinical practice for patients who continue the recommended dosing regimen of IXE treatment. A limitation is the absence of a historic or active treatment comparison for the long-term outcomes.
Overall, the study results have shown that IXE is an appropriate long-term therapy, with highly maintained efficacy and a consistent safety profile for psoriasis treatment. As-observed percentages have been calculated by using the number of patients with nonmissing data at 156 weeks as the denominator. The MI and mNRI results are reported on the basis of the average response rate across multiple imputed data sets. CI, Confidence interval; IXE, ixekizumab; MI, multiple imputation; mNRI, modified nonresponder imputation; PASI, Psoriasis Area and Severity Index, PASI 75/90/100, 75, 90, or 100 improvement from baseline in the Psoriasis Area and Severity Index score, respectively; Q2W, 80 mg ixekizumab every 2 weeks; Q4W, 80 mg ixekizumab every 4 weeks; sPGA (0,1) or (0), static Physician's Global Assessment of 0 or 1 or 0, respectively.
